Filter
1157
Text search:
pharmacy
service
Featured
115
405
Language
Document type
660
184
169
73
32
20
8
4
3
2
1
1
Countries / Regions
67
57
51
50
44
39
35
32
30
30
29
25
24
21
20
19
17
17
16
16
16
13
13
12
12
11
10
9
7
7
7
7
7
6
6
6
6
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
684
55
50
44
32
26
18
1
Toolboxes
94
89
72
52
47
35
33
22
21
18
14
12
10
10
9
8
7
7
7
4
3
3
2
2
An Act to repeal the Dangerous Medicines Act of 1973,to ensure the availability of certain drugs for exclusive medical, scientific and related purposes, while preventing their abuse; to prevent the diversion from lawful trade of controlled chemicals, controlled equipment and controlled materials for
...
SITUATION ANALYSIS AND RECOMMENDATIONS
DHS Further Analysis Reports No. 98
DHS Further Analysis Reports No. 100
Data from the 2000, 2005, and 2011 Demographic and Health Surveys. DHS Trend Reports No. 7
DHS Further Analysis Reports No. 103
Fever Diagnostic Technology Landscape
recommended
1st edition.
Unitaid’s report describes a slate of new devices that can more efficiently identify dangerously ill children so that they can be treated immediately. These tools make it easier to recognize danger signs, and support integrated approaches to reducing childhood deaths from the three
...
"This document has been developed for outpatient oncology
facilities to serve as a model for a basic infection
control and prevention plan. It contains policies
and procedures tailored to these settings to meet minimal
expectations of patient protections as described
in the CDC Guide to Infecti
...
The purpose of this interim guidance is to provide information and insight to assist public policy and
health system leaders in preparing for and responding to an MCE caused by terrorist use of explosives
(TUE). This document provides practical information to promote comprehensive mass casualty ca
...
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
